Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Bayer Yakuhin to Focus on 2 Prospective Blockbusters, Target 200 Billion Yen in Sales in 2013: President Guth
April 9, 2012
- US FDA Recommends Approval of Mirabegron from Astellas
April 9, 2012
- Sanofi-aventis, Alfresa Agree on Joint Development of Antiepileptic Drug
April 9, 2012
- Ohara Pharmaceutical Begins Development of Glucarpidase, Aims to File for Approval in 2014
April 9, 2012
- Eisai Establishes Aricept Director Position
April 6, 2012
- MTPC Complements Alliance with BIKEN to Establish Its Own Vaccine Development Infrastructure
April 6, 2012
- BMKK Posts 1st Increase in Sales Since 2005: President & CEO Emmanuel Blin
April 6, 2012
- Eisai Signs Agreement on Marketing Halaven in 8 Central and Eastern European Countries
April 6, 2012
- Toray Grants German Company Marketing Rights for Antipruritic Agent in Europe
April 6, 2012
- Takeda Considering Manufacturing Plant Move on Power Shortage: Keizai Doyukai Chairman Hasegawa
April 5, 2012
- Nihon Chouzai to Soon Conclude Memorandum with Wholesalers for Provisional Prices
April 5, 2012
- Pharmacists Expect Increase in Use of Amlodipine Generics: Survey
April 5, 2012
- GSK Applies for Fixed-Dose Combination Tablet for Treatment/Prevention of Malaria
April 5, 2012
- Shionogi Sees Positive Results of PIII Study for Anti-HIV Drug
April 5, 2012
- Ajinomoto Pharmaceuticals Obtains Rights to Develop, Commercialize CC Treatment in Japan, Asia
April 5, 2012
- Ajinomoto Pharmaceuticals Ties Up with DKSH Group in Vietnam
April 5, 2012
- Novartis Draws Up Guidelines for MRs on How to Cope in Times of Disaster
April 4, 2012
- Sogo Rinsho HD to Establish New Subsidiary for Full-Scale Market Entry of CRO Business
April 4, 2012
- Genzyme Changes Distributor of 3 Products Including Thymoglobulin to sanofi-aventis
April 4, 2012
- Abbott Receives Approval for Diagnostic Agent for Identification of Patients for Xalkori Administration
April 4, 2012
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…